

Table S1. Datasets used for adult PBPK model building

Study	Cohort	Dose (mg/kg IV)	N	Age (years)	Weight (kg)
Datasets with an ADA-Negative Subset (Model Building Step 1)					
Yoo et al. (1)	Rheumatoid Arthritis	Induction with 3 then 3 q8w	304	50 [21 – 74]	68 [36 – 136]
Brandse et al. (2)	Ulcerative Colitis	Induction with 5	19	36 (27 – 44)	70 (61 – 75)
Shin et al. (3)	Healthy	5 single dose	53	39.4 ± 9.9	79.1 ± 8.3
Takeuchi et al. ^a (4)	Rheumatoid Arthritis	Induction with 3 then 3 q8w	47	53.8 ± 13.4	53.4 ± 10.1
Additional Datasets (Model Building Step 2)					
Lambert et al. (5)	Healthy	5 single dose	41	28.5 [18 – 45]	74.7 [62.3 – 88.6]
Udata et al. (6)	Healthy	10 single dose	48	[18 – 55]	NA
Park et al. (7)	Healthy	5 single dose	71	41 [18 – 55]	78.1 [55.4–99.9]
Maini et al. (8) St. Clair et al. (9)	Rheumatoid Arthritis	Induction with 3 and 10 then 3 and 10 q4w or q8w	197	53 [19 – 80]	NA
Park et al. (10, 11)	Ankylosing Spondylitis	Induction with 5 then 5q8w	110	38 [18 – 66]	76.0 (45.5–122.7)
Gottlieb et al. (12, 13)	Psoriasis	Induction with 5 and 10	17	43 [21 – 69]	91.5 [61 – 165]
Gottlieb et al. (13, 14)	Psoriasis	Induction with 5 then 5 q8w	215	44.4 ± 13.3	93.5 ± 21.1
Adedokun et al. (15)	Ulcerative Colitis	Induction with 5 and 10 then 5 and 10 q8w	484	40 (30 – 52)	77 (66 – 89)
Rutgeerts et al. (16)	Crohn's Disease	5, 10 and 20 single dose then 10 q8w	37	34 [20 – 64]	66 [40 – 102]
Cornillie et al. (17)	Crohn's Disease	Induction with 5 then 5 and 10 q8w	284	36.8 [18 – 76]	NA
Rahman et al. (18)	Rheumatoid Arthritis	Induction with 3 then 3q8w	220	54 (44 – 62)	69.3 (60.1 – 81.0)
Hibi et al. (19)	Behcet Disease	Induction with 5 then 5 q8w	11	37.6 ± 7.4	67.8 ± 17.9
Jatoi et al. (20)	NSCLC	5 on weeks 0, 2, 4, 8, 12	4	72.25	NA
Choe et al. (21)	Rheumatoid Arthritis	Induction with 3 then 3 q8w	160	52.6 ± 11.7	71.9 ± 16.5
Bortlik et al. (22)	Crohn's Disease	Induction with 5 then 5 q8w	84	31 [17 – 62]	NA
Krzysiek et al. (23)	Ankylosing Spondylitis	Induction with 5 then 5 q6w	93	39.5 ± 12.0	NA
Torii et al. (13, 24, 25)	Psoriasis	Induction with 5 then 5 q8w	35	46.9 ± 13.0	68.5 ± 13.4
Sorrentino et al. (26)	Crohn's Disease	3 and 5 q8w	11	37.8	NA
Kavanaugh et al. (27)	Rheumatoid Arthritis	5, 10 and 20 single dose	21	45.5 ± 12.3	NA

Data presented as mean or median and [range], (interquartile range) or ± standard deviation
 'Induction' refers to intensive dosing at weeks 0, 2 and 6 before regular maintenance dosing

^a The dataset included an ADA-negative subset that was used for model building while data from the total population was independently used for model evaluation.

REFERENCES

- (1) Yoo, D.H. *et al.* A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. *Annals of the Rheumatic Diseases* **72**, 1613-20 (2013); doi: 10.1136/annrheumdis-2012-203090.
- (2) Brandse, J.F. *et al.* Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. *Clinical Gastroenterology and Hepatology* **14**, 251-8.e2 (2016); doi: 10.1016/j.cgh.2015.10.029.
- (3) Shin, D., Kim, Y., Kim, Y.S., Kornicke, T. & Fuhr, R. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade) in healthy subjects. *BioDrugs* **29**, 381-8 (2015); doi: 10.1007/s40259-015-0150-5.
- (4) Takeuchi, T. *et al.* Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. *Modern Rheumatology* **25**, 817-24 (2015); doi: 10.3109/14397595.2015.1022297.
- (5) Lambert, J. *et al.* Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. *International Journal of Clinical Pharmacology and Therapeutics* **54**, 315-22 (2016); doi: 10.5414/CP202530.
- (6) Udata, C., Hua, S.Y., Yin, D., Salts, S., Meng, X. & Rehman, M.I. A Phase I pharmacokinetics trial comparing PF-06438179 (a potential biosimilar) and infliximab in healthy volunteers. *Annals of the Rheumatic Diseases* **73**, 494 (2014); doi: 10.1136/annrheumdis-2014-eular.5377.
- (7) Park, W., Lee, S.J., Yun, J. & Yoo, D.H. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. *Expert Rev Clin Immunol* **11 Suppl 1**, S25-31 (2015); doi: 10.1586/1744666X.2015.1090311.
- (8) Maini, R. *et al.* Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. *The Lancet* **354**, 1932-9 (1999); doi: 10.1016/S0140-6736(99)05246-0.
- (9) Williams, S.C.E. *et al.* The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* **46**, 1451-9 (2002); doi: 10.1002/art.10302.
- (10) Park, W. *et al.* A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. *Annals of the Rheumatic Diseases* **72**, 1605-12 (2013); doi: 10.1136/annrheumdis-2012-203091.
- (11) Park, W. *et al.* Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. *Arthritis Research & Therapy* **18**, 25 (2016); doi: 10.1186/s13075-016-0930-4.
- (12) Gottlieb, A.B. *et al.* Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis

- vulgaris. *Journal of the American Academy of Dermatology* **48**, 68-75 (2003); doi: 10.1067/mjd.2003.10.
- (13) Dannepond, C., Maruani, A., Machet, L., Ternant, D., Paintaud, G. & Samimi, M. Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review. *Acta Dermato-Venereologica* **95**, 401-6 (2015); doi: 10.2340/00015555-1980.
 - (14) Gottlieb, A.B. *et al.* The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. *Journal of the American Academy of Dermatology* **67**, 642-50 (2012); doi: 10.1016/j.jaad.2011.10.020.
 - (15) Adedokun, O.J. *et al.* Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. *Gastroenterology* **147**, 1296-307.e5 (2014); doi: 10.1053/j.gastro.2014.08.035.
 - (16) Rutgeerts, P. *et al.* Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. *Gastroenterology* **117**, 761-9 (1999); doi: 10.1016/S0016-5085(99)70332-X.
 - (17) Cornillie, F. *et al.* Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. *Gut* **63**, 1721-7 (2014); doi: 10.1136/gutjnl-2012-304094.
 - (18) Rahman, M.U. *et al.* Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases* **66**, 1233-8 (2007); doi: 10.1136/ard.2006.065995.
 - (19) Hibi, T. *et al.* Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. *Medicine* **95**, e3863 (2016); doi: 10.1097/MD.0000000000003863.
 - (20) Jatoi, A. *et al.* A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. *Supportive Care in Cancer* **12**, 859-63 (2004); doi: 10.1007%2Fs00520-004-0638-x.
 - (21) Choe, J.-Y. *et al.* A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. *Annals of the Rheumatic Diseases* **76**, 58-64 (2017); doi: 10.1136/annrheumdis-2015-207764.
 - (22) Bortlik, M. *et al.* Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. *Journal of Crohn's and Colitis* **7**, 736-43 (2013); doi: 10.1016/j.crohns.2012.10.019.
 - (23) Roman, K. *et al.* Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. *Arthritis Care & Research* **61**, 569-76 (2009); doi: 10.1002/art.24275.
 - (24) Torii, H., Sato, N., Yoshinari, T. & Nakagawa, H. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. *The Journal of Dermatology* **39**, 253-9 (2012); doi: 10.1111/j.1346-8138.2011.01459.x.
 - (25) Torii, H. & Nakagawa, H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. *Journal of Dermatological Science* **59**, 40-9 (2010); doi: 10.1016/j.jdermsci.2010.04.014.
 - (26) Sorrentino, D., Marino, M., Dassopoulos, T., Zarifi, D. & Del Bianco, T. Low dose infliximab for prevention of postoperative recurrence of Crohn's disease: long term follow-up and impact of infliximab trough levels and antibodies to infliximab. *PLOS ONE* **10**, e0144900 (2015); doi: 10.1371/journal.pone.0144900.

- (27) Kavanaugh, A., St Clair, E.W., McCune, W.J., Braakman, T. & Lipsky, P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. *The Journal of Rheumatology* **27**, 841-50 (2000).